SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cell Genesys (CEGE) -- Ignore unavailable to you. Want to Upgrade?


To: SemiBull who wrote (1167)12/17/2001 9:01:51 AM
From: SemiBull  Read Replies (1) | Respond to of 1298
 
7:47AM Cell Genesys (CEGE) 23.10: Reports further clinical data from its multicenter Phase I/II GVAX lung cancer vaccine trial which demonstrated a complete tumor response rate of 12% and a median response duration of greater than 11 months in patients with advanced non small-cell lung cancer who have failed chemotherapy and/or radiation therapy.

finance.yahoo.com